Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).

Date publication

janvier 2017

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEIFFERT Didier

Tous les auteurs :
Pasquier D, Nickers P, Peiffert D, Maingon P, Pommier P, Lacornerie T, Martinage G, Tresch E, Lartigau E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29190707

Résumé

Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer.

Mots clés

Aged, Aged, 80 and over, Humans, Male, Middle Aged, Prostatic Neoplasms, radiotherapy, Radiotherapy, Intensity-Modulated

Référence

PLoS ONE. 2017 ;12(11):e0187794